SUBSCRIBE
SUBSCRIBE
Heather McKenzie

Heather McKenzie

Senior Editor

Heather McKenzie is a professional journalist with more than five years experience in the biopharmaceutical industry. Since joining BioSpace, she has written more than 200 features and breaking news articles with a particular focus in neuroscience and gene therapy. She has also traveled internationally to cover global biotech hubs such as Israel. In previous roles, she has covered current affairs, sports, education and politics. She previously spent eight years as a senior content producer for executive-level business conferences in the pharma/biotech, legal, energy and business strategy sectors. In her free time, Heather enjoys creative writing, spending time with family and playing with her energetic Russian Blue cat Roofus. She hails from Toronto and has also lived in Chicago and Chesapeake, Virginia. You can reach her at heather.mckenzie@biospace.com.

Drug Development
AB Science Announces Significant Survival Data for Masitinib in ALS
The recent survival results of Masitinib will help (ALS) patients to live longer. AB Science has successfully established the sweet spot for masitinib in ALS.
July 19, 2021
 · 
3 min read
 · 
Heather McKenzie
Biotech Bay
Bay Area Biotech Companies Hiring Now
The Biotech Bay region is home to 3,418 life sciences companies and 96,574 employees making an average of $148,285. Here’s a look at a few of the bay area biotech companies hiring now.
July 15, 2021
 · 
6 min read
 · 
Heather McKenzie
Pharm Country
Navigating Biotech Risks from Discovery to Approval
Up and down the development pipeline, there are vulnerabilities. From shareholder expectations and IP protection to clinical trial risk and cyberattacks, it’s a minefield and enlisting a risk management partner is vital.
July 12, 2021
 · 
8 min read
 · 
Heather McKenzie
Business
Evidence Building for a Mix and Match Approach to COVID-19 Vaccines
Morgan had determined that adding one dose of the Moderna or Pfizer-BioNTech mRNA vaccine to one of Oxford-AstraZeneca’s viral vector technology would equal stronger immunity.
July 12, 2021
 · 
5 min read
 · 
Heather McKenzie
Sana employees, pictured in a company laboratory,
Business
Inclusion and Diversity is Paramount to Sana’s Patient-Centric Culture
Sana Biotechnology, a gene and cell therapy hybrid whose mission is to create and deliver engineered cells as medicines for patients, puts the “I” first in Inclusion, Diversity and Equity (IDE).
July 9, 2021
 · 
5 min read
 · 
Heather McKenzie
Business
Promised EAP Date Approaching for Biogen’s Highly Publicized ALS Drug
Tofersen is the furthest along of four ASOs currently in clinical development for ALS and as such, there is quite a bit riding on the results of the VALOR trial which has an estimated completion date of August 31st, 2021.
June 28, 2021
 · 
6 min read
 · 
Heather McKenzie
Intellia President and CEO John Leonard, M.D./Phot
Drug Development
UPDATED: In Major CRISPR Milestone, Intellia Successfully Edits Genes Inside the Body
Interim results from the Phase I study presented at the Peripheral Nerve Society Annual Meeting demonstrated that the investigational therapy, NTLA-2001, greatly reduced the disease-causing protein after a single infusion.
June 27, 2021
 · 
4 min read
 · 
Heather McKenzie
Rafael Henrique/SOPA Images/LightRocket
Drug Development
Will Intellia Make Gene Editing History Saturday?
In what will be a big moment for CRISPR technology, Intellia and development partner, Regeneron Pharmaceuticals will share the world’s first data from a therapy that edits flawed genes inside the body.
June 25, 2021
 · 
2 min read
 · 
Heather McKenzie
Business
Aerosol Scientist: Masks, Saline Cleansers May Have Enduring Value Beyond COVID-19
With COVID-19 ducking for cover and going into an almost full retreat across the U.S., Americans are throwing caution – and masks – to the wind. But many are still nervous, and wondering: How do we protect ourselves in this brave new normal?
June 24, 2021
 · 
4 min read
 · 
Heather McKenzie
Bio NC
BioSpace Publishes 2021 U.S. Life Sciences Salary Report, Examines Salary Growth Despite Challenges
As BioSpace releases its third annual 2021 U.S. Life Sciences Salary Report, there are hopeful surprises and unsettling truths.
June 23, 2021
 · 
4 min read
 · 
Heather McKenzie
Drug Development
Inside ReCode’s New-in-Class Approach to Treating Cystic Fibrosis
The data showed that both experimental therapies restored function in the cystic fibrosis transmembrane conductance regulator gene.
June 17, 2021
 · 
5 min read
 · 
Heather McKenzie
Drug Development
Xilio Rides First Half Momentum to IND Acceptance for Checkpoint Inhibitor
XTX101 is a tumor-selective anti-CTLA-4 monoclonal antibody designed to improve upon the safety of current therapies in the same class.
June 17, 2021
 · 
2 min read
 · 
Heather McKenzie
Drug Development
ENA Respiratory Raises AU$32 Million for Preventative Nasal Spray Against COVID-19
The company’s lead candidate, INNA-051, is an innate immune agonist that directly stimulates the host’s natural immune defense system.
June 16, 2021
 · 
3 min read
 · 
Heather McKenzie
Business
Mnemo Breaks French Series A Record, Targets Greater Tumor Specificity
The Paris-based biotech will use the funds to create targeted immuno-oncology treatments for a broader range of patients with its next-generation CAR-T and epigenetics platform.
June 15, 2021
 · 
3 min read
 · 
Heather McKenzie
Policy
Discovery of New Childhood Form of ALS Could Inform Future Research
Besides providing a sense of hope for children with this devastating disease, this research could offer another clue toward unlocking the mystery behind other forms of ALS.
June 15, 2021
 · 
5 min read
 · 
Heather McKenzie
Load More